American Oriental Bioengineering Inc. (AOB, Financial) filed Quarterly Report for the period ended 2011-09-30.
American Oriental Bioengineering has a market cap of $57.36 million; its shares were traded at around $0.731 with a P/E ratio of 4.3 and P/S ratio of 0.19. American Oriental Bioengineering had an annual average earning growth of 6.5% over the past 5 years.
sales from our prescription pharmaceutical products decreased from $88,667,804 for the nine months ended September 30, 2010 to $72,554,541 for the same period of 2011, or a 18% decrease. The decrease was primarily due to the decrease in sales from SHL powder and CCXA s generic pharmaceutical products and partially offset by the increase in sales from our prescription formulated Jinji capsule; and
Gross profit decreased by $39,234,332, or 34%, for the nine months ended September 30, 2011 compared to the same period of 2010. Gross profit as a percentage of revenues decreased from 52% for the nine months ended September 30, 2010 to 48% in the same period of 2011 mainly due to the new levied urban construction and maintenance tax and educational surcharge.
Advertising costs decreased by $16,764,283, or 62%, from $26,949,663 in the nine months ended September 30, 2010 to $10,185,380 in the same period of 2011. Advertising costs as a percentage of revenue decreased from 12% for the nine months ended September 30, 2010 to 6% for the same period of 2011.
Research and development costs decreased by $2,101,939, or 20%, from $10,754,394 for the nine months ended September 30, 2010 to $8,652,455 in the same period of 2011. Expressed as a percentage of revenue, research and development costs were 6% and 5% for the nine months ended September 30, 2011 and 2010, respectively.
Read the The complete Report
American Oriental Bioengineering has a market cap of $57.36 million; its shares were traded at around $0.731 with a P/E ratio of 4.3 and P/S ratio of 0.19. American Oriental Bioengineering had an annual average earning growth of 6.5% over the past 5 years.
Highlight of Business Operations:
Gross profit decreased by $22,078,020, or 47%, for the third quarter of 2011 compared to the same period of 2010. Gross profit as a percentage of revenues decreased from 52% in the third quarter of 2010 to 47% in the same period of 2011 mainly due to the new levied urban construction and maintenance tax and educational surcharge.sales from our prescription pharmaceutical products decreased from $88,667,804 for the nine months ended September 30, 2010 to $72,554,541 for the same period of 2011, or a 18% decrease. The decrease was primarily due to the decrease in sales from SHL powder and CCXA s generic pharmaceutical products and partially offset by the increase in sales from our prescription formulated Jinji capsule; and
Gross profit decreased by $39,234,332, or 34%, for the nine months ended September 30, 2011 compared to the same period of 2010. Gross profit as a percentage of revenues decreased from 52% for the nine months ended September 30, 2010 to 48% in the same period of 2011 mainly due to the new levied urban construction and maintenance tax and educational surcharge.
Advertising costs decreased by $16,764,283, or 62%, from $26,949,663 in the nine months ended September 30, 2010 to $10,185,380 in the same period of 2011. Advertising costs as a percentage of revenue decreased from 12% for the nine months ended September 30, 2010 to 6% for the same period of 2011.
Research and development costs decreased by $2,101,939, or 20%, from $10,754,394 for the nine months ended September 30, 2010 to $8,652,455 in the same period of 2011. Expressed as a percentage of revenue, research and development costs were 6% and 5% for the nine months ended September 30, 2011 and 2010, respectively.
Read the The complete Report
